The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
New targets and delivery systems for antifungal therapy
Open accessAbstract
Development of new approaches for treatment of invasive fungal infections encompasses new delivery systems for approved and investigational compounds, as well as exploiting the cell membrane, cell wall and virulence factors as putative antifungal targets. Novel delivery systems consisting of cyclodextrins, cochleates, nanoparticles/nanospheres and long circulating ('stealth') liposomes, substantially modulate the pharmacokinetics of existing compounds, and may also be useful to enhance the delivery of antifungal agents to sites of infection. Further insights into the structure-activity relationship of the antifungal triazoles that target the biosynthesis of ergosterol in the fungal cell membrane have led to the development of highly potent broad spectrum agents, including posaconazole, ravuconazole and voriconazole. Similarly, a novel generation of cell-wall active semisynthetic echinocandin 1,3 beta-glucan inhibitors (caspofungin, FK463, and VER-002) has entered clinical development. These agents have potent and broad-spectrum activity against Candida spp, and potentially useful activity against Aspergillus spp. and Pneumocystis carinii. The ongoing convergence of the fields of molecular pathogenesis, antifungal pharmacology and vaccine development will afford the opportunity to develop novel targets to complement the existing antifungal armamentarium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Compounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242
Leidich, S. D., Ibrahim, A. S., Fu, Y., Koul, A., Jessup, C., Vitullo, J., Fonzi, W., Mirbod, F., Nakashima, S., Nozawa, Y., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.26078 · Cited by 241
Self-citation
Cited by
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Antifungal photodynamic therapy
Donnelly, R. F., McCarron, P. A., & Tunney, M. M. (2008) · Microbiological Research · doi:10.1016/j.micres.2007.08.001 · Cited by 453
The role of nanotechnology in the treatment of viral infections
Singh, L., Kruger, H. G., Maguire, G. E. M., Govender, T., & Parboosing, R. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936117713593 · Cited by 360
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Posaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Metadata
- Authors
- Walsh, T. J., Viviani, M.-A., Arathoon, E., Chiou, C., Ghannoum, M., Groll, A. H., & Odds, F. C.
- Venue
- Medical Mycology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-01
- Volume
- 38
- Issue
- s1
- Pages
- 335-347
- ISSN
- 0268-1218 (ISSN-L)
- 1369-3786
- 1460-2709
- OpenAlex
- W2061582023
- Cited by
- 161
- References
- 3
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New targets and delivery systems for antifungal therapy. https://app.cochat.ai/papers/10.1080/mmy.38.s1.335.347
- The paper
- Walsh, T. J., Viviani, M.-A., Arathoon, E., Chiou, C., Ghannoum, M., Groll, A. H., & Odds, F. C. (2000). New targets and delivery systems for antifungal therapy. Medical Mycology. https://doi.org/10.1080/mmy.38.s1.335.347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.